Pharma’s initial approach to adjusting to life post-COVID was to digitize its paper sales aids. That strategy has led to a flood of failed digital product launches, a study shows. Graphite’s Jon Hume and Nabriva Therapeutics’ Kimberly Coleman Clotman break down the findings.
Thank you for accessing MM+M.
Create your free account or log in to continue reading this premium content.